Table 4. Antimicrobial Use Within 30 days Prior to Healthcare-associated Infections.
Antimicrobial Agent | Case Subjects N=103 | Control Subjects N=195 | OR (95%CI) | p-valuea |
---|---|---|---|---|
n (%) | ||||
Amikacin | 13 (12.6) | 1 (0.5) | 13.07 (2.96, 57.66) | 0.001 |
Ampicillin | 9 (8.7) | 6 (3.1) | 1.91 (0.84, 4.32) | 0.12 |
Ampicillin-sulbactam | 9 (8.7) | 12 (6.1) | 1.22 (0.64, 2.34) | 0.54 |
Aztreonam | 7 (6.8) | 6 (3.1) | 1.59 (0.70, 3.60) | 0.27 |
Carbapenems | 33 (32.0) | 20 (10.3) | 2.32 (1.44, 3.74) | 0.001 |
Cefazolin | 9 (8.7) | 24 (12.3) | 0.84 (0.47, 1.47) | 0.54 |
Cefepime | 20 (19.4) | 19 (9.7) | 1.53 (0.94, 2.48) | 0.09 |
3rd generation cephalosporinb | 13 (12.6) | 15 (7.7) | 1.36 (0.76, 2.41) | 0.30 |
Clindamycin | 3 (2.9) | 6 (3.1) | 1.00 (0.42, 2.40) | 1.00 |
Daptomycin | 6 (5.8) | 5 (2.6) | 1.63 (0.66, 4.00) | 0.29 |
Gentamicin | 14 (13.6) | 15 (7.7) | 1.28 (0.75, 2.18) | 0.36 |
Levofloxacin | 21 (20.4) | 21 (10.8) | 1.51 (0.94, 2.42) | 0.09 |
Linezolid | 22 (21.4) | 12 (6.2) | 2.37 (1.33, 4.20) | 0.003 |
Macrolidec | 19 (18.5) | 19 (9.7) | 1.53 (0.87, 2.68) | 0.14 |
Metronidazole | 25 (24.3) | 38 (19.5) | 1.13 (0.77, 1.64) | 0.54 |
Oxacillin | 6 (5.8) | 12 (6.2) | 0.85 (0.42, 1.70) | 0.64 |
Piperacillin-tazobactam | 73 (70.9) | 101 (51.8) | 1.46 (1.04, 2.06) | 0.029 |
Polymyxin B | 11 (10.7) | 0 (0) | 1.13 (1.28, 3.54) | <0.001 |
Tigecycline | 10 (9.7) | 2 (1.0) | 5.16 (1.65, 16.13) | 0.005 |
Tobramycin | 31 (30.1) | 34 (17.4) | 1.57 (0.99, 2.47) | 0.05 |
Trimethoprim-sulfamethoxazole | 14 (13.6) | 4 (2.1) | 3.62 (1.56, 8.39) | 0.003 |
Vancomycin | 78 (75.3) | 104 (53.3) | 1.57 (1.12, 2.22) | 0.001 |
Bivariate Analyses
Cefotaxime, ceftriaxone, ceftazidime
Erythromycin or azithromycin